Michael Mamoun, M.D.


Executive Medical Director
Board Certified in General & Adult Psychiatry
Board Certified in Addiction Medicine

Michael Mamoun, M.D. is a physician who is board-certified in psychiatry by the American Board of Psychiatry and Neurology, and also board-certified in Addiction Medicine by the American Board of Addiction Medicine. Doctor Mamoun completed his residency training at the Neuropsychiatric Institute of the UCLA Medical Center. UCLA is consistently ranked in the top 10 institutions for psychiatry and medical training in the U.S.

Dr. Mamoun is skilled in treating the entire spectrum of mental health conditions, including ADHD, anxiety, and mood disorders. He is also skilled in treating substance abuse disorders, including those for prescription drug use as well as recreational drugs. Dr. Mamoun has treated a wide range of patients in multiple clinical settings, including: private practice, UCLA and other university medical centers,  multiple veterans’ medical centers, county and public mental health clinics, non-profit medical and mental health clinics, and community hospitals. He has previously served as the Director of Psychiatric Services at Homeless Healthcare Los Angeles and has volunteered at the non-profit Venice Family Clinic. Originally from Chicago, Dr. Mamoun attended college and medical school at the University of Illinois.

Doctor Mamoun is also actively involved in medical research in addition to clinical practice. His main work is through the Brentwood Biomedical Research Institute in affiliation with the UCLA and VA Medical Centers. His research projects utilize brain imaging in order to better understand the nature and treatment of tobacco dependence and other drug addictions.


Link to Patient Reviews on Vitals.com
Link to Patient Reviews on Yelp.com
Link to Patient Reviews on Healthgrades.com

 Link to Recent Published Research Studies (through ResearchGate)


Recently published research studies:

April 2015:
Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date
CNS Drugs

August 2014:
Radiation dosimetry and biodistribution of the translocator protein radiotracer [(11)C]DAA1106 determined with PET/CT in healthy human volunteers.
Nuclear Medicine and Biology

May 2014:
Brain Nicotinic Acetylcholine Receptor Availability and Response to Smoking Cessation Treatment: A Randomized Trial.
JAMA (Journal of the American Medical Association) Psychiatry. MRI & PET brain imaging study.

July 2013:
Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density.
Neuropsychopharmacology. 2013 Jul;38(8):1548-56.  PET neuroimaging study.

June 2013:
Up-regulation of nicotinic acetylcholine receptors in menthol cigarette smokers
International Journal of Neuropsychopharmacology. 2013 Jun;16(5):957-66. PET neuroimaging study.



patients choice awards